Title :

Alzheimer's disease cerebro-spinal fluid biomarkers: a clinical research tool sometimes useful in daily clinical practice of memory clinics for the diagnosis of complex cases

Author(s) :

Magnin, Eloi [Auteur]
Dumurgier, Julien [Auteur]
Bouaziz-Amar, Elodie [Auteur]
Bombois, Stephanie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Wallon, David [Auteur]
Gabelle, Audrey [Auteur]
Lehmann, Sylvain [Auteur]
Blanc, Frederic [Auteur]
Bousiges, Olivier [Auteur]
Hannequin, Didier [Auteur]
Jung, Bongnam [Auteur]
Miguet-Alfonsi, Carole [Auteur]
Quillard-Muraine, Muriel [Auteur]
Pasquier, Florence [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Peoc''h, K. [Auteur]
Laplanche, Jean-Louis [Auteur]
Hugon, Jacques [Auteur]
Paquet, Claire [Auteur]

Journal title :

La Revue de medecine interne

Abbreviated title :

Rev. Med. Interne

Volume number :

38

Pages :

250-255

Publication date :

2017-04-01

ISSN :

0248-8663

English keyword(s) :

Cerebro-spinal fluid
Biomarkers
Lumbar puncture
Alzheimer''s disease

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The role of biomarkers in clinical research was recently highlighted in the new criteria for the diagnosis of Alzheimer's disease. Cerebro-spinal fluid (CSF) biomarkers (total Tau protein, threonine 181 phosphorylated Tau ...
Show more >The role of biomarkers in clinical research was recently highlighted in the new criteria for the diagnosis of Alzheimer's disease. Cerebro-spinal fluid (CSF) biomarkers (total Tau protein, threonine 181 phosphorylated Tau protein and amyloid Aβ1-42 peptide) are associated with cerebral neuropathological lesions observed in Alzheimer's disease (neuronal death, neurofibrillary tangle with abnormal Tau deposits and amyloid plaque). Aβ1-40 amyloid peptide dosage helps to interpret Aβ1-42 results. As suggested in the latest international criteria and the French HAS (Haute Autorité de santé) recommendations, using theses CSF biomarkers should not be systematic but sometimes could be performed to improve confidence about the diagnostic of Alzheimer's disease in young subjects or in complex clinical situations. Future biomarkers actually in development will additionally help in diagnostic process (differential diagnosis) and in prognostic evaluation of neurodegenerative diseases.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:29:21Z